Search results

Jump to navigation Jump to search

Google site results

Loading...

Wiki results

  • ...h an interest in clinical cytogenetics, molecular genetics and genomics in cancer. [[Contact us]] for more information.''' [[File:Circos.png|100px|link=Main_Page]] '''Cancer Genomes''' [[Hematologoic and Lymphoid]] | [[Solid Tumors]] | [[CNS]] | [[P
    7 KB (905 words) - 22:59, 20 November 2017
  • == Genes == * Cancer Genes A
    10 KB (1,089 words) - 22:30, 20 November 2017
  • ...h an interest in clinical cytogenetics, molecular genetics and genomics in cancer.''' ...ermission from the copyright holder, ©International Agency for Research on Cancer.''|alt=]]
    7 KB (1,032 words) - 10:43, 5 March 2024
  • == Genes Involved == ...t and t(14;19)(q32;q13) in lymphoproliferative disorders. Genes Chromosome Cancer 15:38–47CrossRef
    4 KB (537 words) - 21:44, 20 July 2016
  • "KIT Proto-Oncogene Receptor Tyrosine Kinase"; "V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog"; PBT; "Stem C ==Cancer Category/Type==
    7 KB (1,047 words) - 14:32, 12 December 2023
  • ...page can be found at [[HAEM4:Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged]]. ==Cancer Category / Type==
    19 KB (2,659 words) - 14:32, 13 December 2023
  • .... Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics. !Relevant Genes (if known)
    23 KB (3,285 words) - 15:49, 13 September 2019
  • .... Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics. !Relevant Genes (if known)
    23 KB (3,285 words) - 16:56, 8 August 2020
  • .... Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics. !Relevant Genes (if known)
    23 KB (3,282 words) - 11:49, 14 June 2019
  • ...>Diaz JI, Mora LB, Hakam A. The Mainz Classification of Renal Cell Tumors. Cancer Control. 1999 Nov;6(6):571-579</ref> ...ton CJ. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014 Sep 8;26(3):319-30.</ref>
    3 KB (421 words) - 11:29, 22 August 2016
  • ...Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics. |'''Genes'''
    17 KB (2,298 words) - 16:42, 22 April 2021
  • ==Cancer Category/Type== ...scular endothelial growth factor (''VEGF'') (Merdzhanova et al., 2010). In cancer, ''SRSF2'' variants have been implicated in leukemia and myeloid disorders
    16 KB (2,281 words) - 14:50, 12 December 2023
  • ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==
    14 KB (2,044 words) - 10:09, 27 February 2024
  • Thank you for volunteering to help curate the Compendium of Cancer Genome Aberrations (CCGA)! Your help will make this resource a valuable to ...“Disease pages”. The CCGA is especially interested in the curation fusion genes/mutations that arise in disease, esp. in the hematological cancers. Howeve
    7 KB (1,171 words) - 17:30, 23 April 2019
  • ...ed from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics. ...urvival in a cohort of MDS or AML patients treated with azacitidine. Blood Cancer J 2013;3:e155.[https://www.ncbi.nlm.nih.gov/pubmed/24185502]</ref><ref name
    38 KB (5,270 words) - 17:10, 30 April 2020
  • ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==
    19 KB (2,651 words) - 14:40, 13 December 2023
  • ==Cancer Category/Type== Breast Cancer / Epithelial Tumours of the Breast
    19 KB (2,737 words) - 13:17, 29 February 2024
  • ==Cancer Category/Type== ...ET2 and WT1 physically interact, suggesting overlapping pathways for these genes in AML (Wang et al., 2015). ''TET2'' mutations increase the response of low
    26 KB (3,824 words) - 15:01, 12 December 2023
  • ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==
    15 KB (1,965 words) - 14:30, 13 December 2023
  • Patricia V. Hernandez, M.D., Washington University School of Medicine ==Cancer Category / Type==
    15 KB (2,067 words) - 14:23, 13 December 2023
  • ==Cancer Category/Type== ===Role in Cancer===
    20 KB (2,904 words) - 03:02, 13 August 2018
  • ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==
    19 KB (2,643 words) - 13:51, 25 February 2024
  • ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==
    31 KB (4,325 words) - 13:55, 25 February 2024
  • ...&t=1s <u>A Resource for our Clinical Genomics Community: the Compendium of Cancer Genome Aberrations (CCGA) - YouTube</u>]''' ''iv)    Research/experience in disease/genes of interest''
    10 KB (1,712 words) - 14:21, 12 December 2023
  • ==Cancer Category/Type== ...tyrosine kinase receptor gene FGFR1, located in 8p11, and several partner genes, including ZMYM2 (wang et al).
    10 KB (1,469 words) - 17:05, 11 October 2018
  • ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==
    34 KB (4,782 words) - 16:37, 20 December 2023
  • ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==
    20 KB (2,747 words) - 14:28, 13 December 2023
  • ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==
    25 KB (3,503 words) - 14:24, 13 December 2023
  • Hui Chen, MD, PhD, The University of Texas MD Anderson Cancer Center ==Cancer Category/Type==
    9 KB (1,336 words) - 16:42, 16 April 2024
  • Cancer Metastasis Rev (2014) 33:1109–1124 PMID:[http://www.ncbi.nlm.nih.gov/pubm ...gnature PI3K/AKT and mTOR pathways elevated; high expression of several genes representing targets for immunotherapy including PDCD1, CD247, PDCD1LG2, CT
    8 KB (1,050 words) - 16:48, 19 August 2016
  • ...yrosine kinase; Abelson tyrosine-protein kinase 1; ABL; JTK7; p150; c-ABL; v-abl; CHDSKM; c-ABL1; bcr/abl ==Cancer Category/Type==
    12 KB (1,695 words) - 13:43, 12 December 2023
  • ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==
    21 KB (2,936 words) - 14:33, 13 December 2023
  • ...Table derived from Chun et al., 2018 [PMID 30554732] with permission from Cancer Genetics. |'''Relevant Genes'''
    40 KB (5,707 words) - 22:25, 7 November 2020
  • ...inal page can be found at [[HAEM4:B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged]]. ==Cancer Category / Type==
    12 KB (1,796 words) - 14:21, 13 December 2023
  • ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==
    22 KB (3,077 words) - 14:26, 13 December 2023
  • ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==
    30 KB (4,118 words) - 14:20, 13 December 2023
  • ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==
    22 KB (3,152 words) - 14:16, 13 December 2023
  • ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==
    48 KB (6,794 words) - 14:27, 13 December 2023
  • ==Cancer Category/Type== '''Breast Cancer'''
    36 KB (5,335 words) - 14:18, 12 December 2023
  • |Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center |Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia
    61 KB (7,864 words) - 16:23, 16 April 2024
  • ==Cancer Category/Type== Colorectal cancer
    13 KB (1,790 words) - 18:29, 5 January 2019
  • ::Mismatch repair cancer syndrome :Familial non-medullary thyroid cancer
    38 KB (3,868 words) - 13:56, 12 December 2023
  • ==Cancer Category/Type== ...e [5]. Both hypo- and hypermethylation may be pathogenic in the context of cancer. Global hypomethylation may be associated with genomic instability. The ami
    14 KB (1,939 words) - 18:10, 5 January 2019
  • ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==
    14 KB (1,883 words) - 14:30, 13 December 2023
  • ...Table derived from Liu et al., 2020 [PMID 32434132] with permission from Cancer Genetics. ...ehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer|url=https://pubmed.ncbi.nlm.nih.gov/23083876|journal=The Journal of Urology
    42 KB (5,820 words) - 13:40, 19 May 2021
  • ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==
    14 KB (1,944 words) - 14:29, 13 December 2023
  • ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==
    27 KB (3,643 words) - 14:36, 13 December 2023
  • ...able derived from Akkari et al., 2020 [PMID 32302940] with permission from Cancer Genetics. All percentages are approximate. |[[KMT2A Partner Genes|KMT2A]] (11q23) rearrangements*
    33 KB (4,848 words) - 10:50, 26 July 2021
  • ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==
    17 KB (2,372 words) - 14:31, 13 December 2023
  • ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==
    31 KB (4,371 words) - 14:25, 13 December 2023

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)